The United States Food and Drug Administration issued a statement confirming the convalescent plasma as a treatment medication for COVID-19.
According to the latest report issued by the FDA on Sunday, August 23, 2020, convalescent plasma has already treated about 70,000 patients.
Convalescent plasma is made by mixing the blood of people who have recovered from Coronavirus.
While issuing White House briefing on Coronavirus, the US President Donald Trump said, “Today I am pleased to make a truly historic announcement in our battle against the China virus that will save countless lives.” “Today’s action will dramatically increase access to this treatment, ” he added.
Initially, President Trump had accused healthcare officials of playing politics about the EUA for convalescent plasma. During the last week’s briefing, Trump said that the FDA was not granted due to politics.
Sources from the White House Coronavirus Task Force also informed the media that the FDA had review critical data to inform the decision by the EUA.
Trump’s administration has also stated that bringing a medical solution to Americans is within the US government’s rights and powers and that they need not consult anyone.
Convalescent plasma is collected from x-covid-19 patients. The study about the impact of Convalescent plasma on patients was initiated by the end of March this year. The report from the study reveals that its impact on COVID-19 patients is positive as more than 60,000 patients have already been treated.
However, convalescent plasma is in limited supply since its processing depends on blood donors. Limitation of the dose is just one of the challenges as there is also a lack of data from clinical trials in regards to convalescent plasma. Nonetheless, the trials are underway.
COVID-19 has posed negative impacts on various sectors across the world since its eruption in Wuhan, China, late last year.